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Background: Coronary artery disease (CAD) is a major cause of death in India. Data on
outcome of CAD is scarce in the Indian population. This study determined the character-
istics, treatment and one-year outcomes of acute coronary syndrome (ACS) in an Indian
Cardiac Centre.
Methods: We carried out a cross sectional retrospective analysis of 1468 ACS patients
hospitalized between January 2008 and December 2010 and followed up for 1 year in the
Institute of Cardiovascular Diseases, Madras Medical Mission, Chennai. Mortality at 1 year,
its determinants and 1 year major adverse cardiac events (MACE) were determined.
Results: The patients were aged 62.2  11.2 years; males (75.2%) and had ST segment
elevation myocardial infarction (STEMI) (33.9%), non ST segment elevation myocardial
infarction (44.2%) and unstable angina (21.9%). Key pharmacotherapy included aspirin
(98.2%), clopidogrel (95.1%), statins (95.6%), angiotensin converting enzyme inhibitor/
angiotensin receptor blocker (50.6%) and beta blocker (83.1%). Angiography rate was 80.6%.
In the STEMI group, 53.3% had primary angioplasty, 20.3% were thrombolysed and 16.1%
received sole medical therapy. Overall coronary artery bypass graft rate was 12.4%. At one
year, all-cause mortality and composite MACE were 2.5% and 9.7%, respectively. MACE
included death (2.5%), reinfarction (4.0%), resuscitated cardiac arrest (1.8%), stroke (1.1%)
and bleeding (0.4%). Main factors associated with mortality were combined left ventricular
systolic and diastolic dysfunction (OR ¼ 20.0, 95% CI ¼ 6.63e69.4) and positive troponin I
(OR ¼ 12.56, 95% CI ¼ 1.78e25.23). Troponin I independently predicted mortality.
Conclusions: ACS population was older than previously described in India. Evidence-based
pharmacotherapy and interventions, and outcomes were comparable to the developed
nations.
Copyright ª 2013, Cardiological Society of India. All rights reserved.(S. Isezuo).
2013, Cardiological Society of India. All rights reserved.
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It is projected that coronary artery disease (CAD) would rise in
the developing nations by 120% and 137% in women andmen,
respectively by 2020.1 Of all the developing nations, India is
undergoing the most rapid epidemiologic transition from
communicable to non-communicable diseases and at the
third stage of the transition characterized by high burden of
atherothrombotic dominated non-communicable diseases.2
Coronary artery disease constitutes the largest contributor to
cardiovascular disease burden in India. A review of cross
sectional surveys in 2008 showed that 3e4% and 8e10% of
rural and urban Indian dwellers, respectively, have CAD.3 This
represented a 2-fold increase in rural and 6-fold increase in
urban prevalence over a period of 40 years. In India CAD is the
leading cause of death accounting for 1.46 million deaths
which represented 14% of all-cause mortality in 2004.4 It is
projected that by 2020 ischemic heart disease will result in 2.5
million deaths while daily adjusted life years (DALYs) lost due
to CAD will rise to about 7.67e14.4 million in men and 5.6e7.7
million in women in India.3 Compared to the western world,
CAD epidemiology in India is characterized by premature
occurrence in the young and low/middle income group, high
mortality and high prevalence of diabetes.5,6
Acute coronary syndrome (ACS) is a spectrum of diseases
comprising unstable angina (UA), ST segment elevation
myocardial infarction (STEMI) and non ST segment elevation
myocardial (NSTEMI). It is the major cause of mortality in CAD
and represents a principal form of its clinical presentation. The
results of a multicentre ACS Registry in India (CREATE) demon-
strated a 30 day mortality of 5.6%.6 The outcome of ACS may
however be influenced by the level of health care or hospital
setting. Furthermore, there is limited data on the intermediate
and long-term outcomes of ACS in India. We determined the
characteristics, treatment and one-year outcome of patients
with ACS in the Institute of Cardiovascular Disease, Madras
MedicalMission, a tertiary cardiac care centre in Chennai, India.2. Methods
2.1. Study population
The study population consisted of consecutive ACS patients
aged 18 years who were hospitalized and followed up for a
minimum of 12 calendar months between 1st January 2008
and 31st December 2010 at the Institute of Cardiovascular
Disease, Madras Medical Mission Chennai, India. The institute
is a specialized cardiac centre with 21 bed coronary care unit
(CCU), cardiac surgery facility and 2 state-of-the art cardiac
catheterization laboratories performing high volume percu-
taneous coronary interventions (PCI). It provides 24 h service
including 24 h on-the-spot consultant coverage in the CCU
and cardiac laboratory.
2.2. Study protocol
The inclusion criteria included ACS defined using documented
triad of characteristic ischemic symptoms, ECG changes andcardiac biomarker (troponin I) status.7 STEMI was defined as
characteristic angina symptoms and ST segment elevation of
1 mm in at least 2 adjacent limb leads or 2 mm in at least 2
contiguous precordial leads and/or presumed new onset left
bundle branch block (LBBB) on initial 12-lead ECG and troponin
level greater than hospital cut-off point of 0.012 ug/L. NSTEMI
was diagnosed if there were angina symptoms with ST
segment depression 1 mm or T wave abnormalities and
elevated troponin level above 0.012 ug/L. Unstable angina was
defined as documented angina symptoms at rest with ST
segment depression or T wave abnormalities without ST
segment elevation or elevated troponin level (below 0.012 ug/L).
Patients with ST segment elevation following coronary artery
bypass graft (CABG) or PCI were excluded.
Standard structured questionnaire was utilized to collect
data on demography including age, gender and nationality.
Cardiovascular risk factors including alcohol consumption and
smoking were recorded. Alcohol consumption greater than 40
drinks (males) or 30 drinks (females) per week was considered
significant. Smoking of 10 or more cigarettes per day was
considered significant. Type 2 diabetes was diagnosed as fast-
ing blood glucose >126 mg/dL (7 mmol/L) or 2 h glucose level
greater than (200mg/dL) 11.1mmol/L or history of diabetes and
hypertension as history of hypertension/antihypertensive
medication and/or blood pressure 140/90. Patients with high
density lipoprotein cholesterol (HDL) level <40 mg/dl (men) or
<50 mg/dl (women), and triglyceride level 150 mg/dl, serum
total cholesterol >200 mg/dl or LDL cholesterol >130 mg/dl
were considered to have dyslipidaemia. Information on family
history of CAD was recorded.
The period from onset of symptoms to presentation in the
hospital, baseline clinical characteristics and history of prior
myocardial infarction (MI) or CABG or PCI were determined.
Data on other laboratory investigations/procedures including
renal biochemistry, left ventricular function, coronary angi-
ography and ECG determined anatomical site of infarction in
STEMIwere collected. The treatment strategies including drug
treatment, PCI and CABG as well as complications and out-
comes were recorded.
All-cause mortality at 1 year as well as mortality at 7 days,
30 days, 6 months and 1 year major adverse cardiovascular
events (MACE) including deaths, reinfarction, stroke, resusci-
tated cardiac arrest and major bleeding were determined.
Myocardial reinfarction was defined as new troponin eleva-
tion with either new onset chest pain/discomfort or ECG
changes consistentwith infarction or both. Strokewas defined
as focal neurological deficit of vascular origin lasting more
than 24 h and confirmed by computed tomogram scan. Major
bleeding was defined as a fall in hemoglobin of 5 g/dl or hae-
motocrit of 15% and cardiac arrest as resuscitated sustained
ventricular tachycardia or ventricular fibrillation or asystole.
2.3. Statistical analysis
Data analysis was done using Statistical Package for Social
Sciences software (SPSS Inc Chicago, Illinois version 17.0). Like
most retrospective studies there was missing data. These
were missing completely at random (MCAR) probably due to
incomplete entry or loss of record. The analyses in which
these data was involved were descriptive. We therefore
Table 1 e General characteristic of patients.
Parameter Male Female Total p-value
No (%) 1104 (75.2) 364 (24.8) 1468 (100)
Age (years) 61.5  11.5 64.1  10.1 62.2  11.2 <0.0001
50 years n (%) 197 (17.8) 33 (9.1) 230 (15.7) <0.0001
51e60 years n (%) 328 (29.7) 104 (28.6) 432 (29.4) 0.07
70e70 years n (%) 332 (30.1) 128 (35.1) 460 (31.3) 0.07
>70 years n (%) 247 (22.4) 99 (27.2) 346 (23.6) 0.06
STEMI n (%) 412 (37.3) 86 (24.5) 498 (33.9) <0.0001
NSTEMI n (%) 476 (43.1) 172 (47.5) 648 (44.2) 0.01
U Angina n (%) 216 (19.6) 106 (29.0) 322 (21.9) <0.0001
Hypertension n (%) 705/1081 (65.2) 283/360 (78.6) 988/1441 (68.6) <0.0001
Dyslipidaemia n (%) 715/803 (89.0) 217260 (83.4) 932/1063 (87.7) 0.01
Diabetes n (%) 605/1068 (56.6) 228/356 (64.3) 834/1424 (58.6) 0.01
Smoking n (%) 350/1046 (33.5) 4/295 (1.4) 354/1341 (26.4) <0.0001
F History n (%) 123/912 (13.4) 23/295 (7.8) 146/1207 (12.0) 0.01
Alcohol consumption n (%) 162/933 (17.4) 4/278 (1.1) 166/1211 (13.7) <0.0001
RF 3 n (%) 432/1082 (33.9) 149/359 (41.5) 581/1441 (40.3) 0.6
Prior MI n (%) 329/980 (33.6) 92/321 (28.7) 421/1301 (32.4) 0.10
CAG n (%) 853/1052 (81) 254/339 (74.9) 1107/1373 (80.6) 0.01
MVD n (%) 465/770 (60.4) 131/220 (59.6) 596/990 (60.2) 0.06
CAG: Coronary angiography. F: Family. MVD: Multiple vessel disease. RF: Risk factors.
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ensure retention of the size of the study population, statistical
power and representativeness of our results. Continuous
variables were expressed as mean  SD and compared using
independent t-test (2-tailed). Discrete variables were pre-
sented as percentages (proportions) and compared using Chi
square or Fisher’s Exact test, as appropriate. We used uni-
variate analysis to determine the effect of the following fac-
tors on one-year mortality: age, gender, ACS type (STEMI,
NSTEMI and UA), risk factor, prior myocardial infarction, prior
CABG, left ventricular function, number of diseased vessels,
creatinine, ESR and leukocyte count. Factors that were sig-
nificant predictors of outcome were used as independent
variables in multiple logistic regression analysis aimed at
determining the independent predictors of mortality (depen-
dent variable). A p-value <0.05 was considered statistically
significant.61.2, 61%
36.2, 36%
2.2, 2% 0.4,1%
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Fig. 1 e Anatomical sites of infarction.3. Results
A total of 1504 patients with acute coronary syndrome (ACS)
were admitted during the 3-year study period (2008e2010).
Fifty six (3.7%) patients were lost to follow up and excluded
from analysis. The remaining 1468 were made of STEMI
(33.9%), NSTEMI (44.2%) and UA (21.9%) patients. Table 1
shows the general characteristics of the study population.
The patients were aged 62.2  11.2 years (range: 27e97 years,
median 62 years). They weremostly (60.8%) in the 50e70 years
age group and were predominantly males 1104 (75.2%) (Table
1). Compared to males, the females were older (64.1  10.1
vs 61.5  11.5 years; p < 0.0001). Dyslipidaemia (87.7%), hy-
pertension (67.3%) and diabetes (58.6%) were the leading risk
factors for CAD. Other risk factors included cigarette smoking
(26.4%) and family history of CAD (12.0%). LowHDL cholesterol
(80.7%) was the most frequent lipid abnormality. About 40.3%
of patients had 3 or more risk factors for CAD. Males had ahigher proportion of patients who were cigarette smokers
than females (33.5% vs 1.4%, p < 0.0001). Compared to males,
females had higher prevalence of hypertension (78.6 vs 65.2%;
p < 0.0001) and diabetes (64.3 vs 56.6%; p ¼ 0.01).
In the STEMI group, 120 (75.9%) patients presented in Killip
Class I. The anatomical sites of infarction (Fig. 1) were mainly
the anterior (61.2%) and inferior (36.2%) walls. Males were
more likely to have STEMI (82.7 vs 71.4%, p < 0.0001) while
females were more likely to have NSTEMI/UA (28.6 vs 17.3%,
p < 0.0001) (Table 2). Compared to NSTEMI/UA, patients with
STEMI were significantly younger (60.4  10.5 vs 63.0  11.5
years, p < 0.0001), had higher heart rate (84.2  18.9 vs
81.3  18.2 beat per minute), lower systolic blood pressure
(131.6  25.1 vs 138.7  26.5 mmHg p < 0.0001) and lower left
ventricular systolic ejection fraction (41.0  9.2 vs 45.0  14.2,
Table 2).
Coronary angiography (CAG) was performed in 80.6% of
patients. The angiography rate was significantly higher in
the STEMI than NSTEMI/UA group (84.3 vs 77.1%, p ¼ 0.0001)
(Table 2). Patients who had CAG were significantly younger
(61.1 10.5 vs 65.9 12.9; p< 0.0001). Specific diseased vessels
included the left anterior descending artery (77.4%), right
Table 2 e Comparison of patients with STEMI and NSTEMI/UA.
Parameter STEMI NSTEMI/UA Total p-value
No (%) 498 (33.9) 970 (66.1) 1468 (100)
Age (years) 60.4  10.5 63.0  11.5 62.2  11.2 <0.0001
Age >70 years n (%) 84 (16.9) 262 (27.0) 346 (23.6) <0.0001
Male n (%) 412 (82.7) 692 (71.3) 1104 (75.2) <0.0001
Female n (%) 86 (17.3) 278 (28.7) 364 (24.8) <0.0001
RF 3 (%) 232/489 (47.4) 349/952 (36.7) 581/1441 (40.3) 0.01
HTN duration (years) 6.9  5.9 8.3  7.3 7.8  6.9 0.01
SBP (mmHg) 131.6  25.1 138.7  26.5 136.3  26.3 <0.0001
H Rate (bpm) 84.2  18.9 81.3  18.2 82.3  18.5 0.01
LV EF (%) 41.0  9.2 45.0  14.2 43.6  12.7 <0.0001
SVD (%) 169/368 (45.9) 226/623 (36.3) 395/991 (39.6) 0.002
CAG (%) 404/479 (84.3) 703/912 (77.1) 1107/1391 (79.6) 0.001
PCI (%) 225/422 (53.3) 292/802 (36.4) 517/1224 (42.2) <0.0003
Frq of hospitalization 1.2  0.5 1.3  0.7 1.2  0.6 <0.0001
CAG: Coronary angiography. Freq: Frequency. H: Heart. HTN: Hypertension. LVEF: Left ventricular ejection fraction. Multiple vessel disease. PCI:
Percutaneous coronary intervention. RF: Risk factors. SBP: Systolic blood pressure. SVD: Single vessel disease.
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onary artery (12.6%) and others (5.2%) (Fig. 2). Single, double
and triple vessel diseases were observed in 39.5%, 29.1% and
30.5%ofpatients, respectively.Nine (0.9%)patientshadnormal
epicardial coronary arteries (Fig. 3). Single vessel disease was
more frequent in the STEMI group (45.9 vs 36.3%;p< 0.01)while
multiple vessel involvement, thoughhigher inNSTEMI/UA,did
not differ significantly between the two groups.
The rates of use of evidence-based pharmacotherapy and
interventions are shown in Table 3. Aspirin, clopidogrel and
lipid modifying drugs were used in 98.2%, 95.1% and 94.2% of
patients, respectively. Other evidence-based drugs that were
used included beta blockers (83.1%), angiotensin converting
enzyme inhibitors (ACEI)/angiotensin receptor blockers (ARB)
50.6% and calcium channel blockers (CCB) (11.9%). Overall,
96.4% of patients had at least one or combinations of ACEI/
ARB and BB (Table 3). Anticoagulant medication was used in
33.8% of patients, and this was predominantly (92.4%) low
molecular weight heparin. Of the 384 referred patients with
information on antiplatelet therapy, 193 (50.2%) had pre-
referral antiplatelet treatment including aspirin (46.6%) and
clopidogrel (45.8%).
The time from onset of symptoms to presentation ranged
from 5 min to 120 h (median 5 h, mode 24 h) in patients with
STEMI 53.3%. In the STEMI group, 20.3% of patients were0
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Fig. 2 e Pattern of coronary artery lesion. LAD: Left anterior
descending artery. LCX: Left circumflex artery. LMCA: Left
main coronary artery. RCA: Right coronary artery. Perc:
Percentage.thrombolysed predominantly using streptokinase (94.0%),
while 53.3% and 10.3% had primary PCI and CABG, respec-
tively. Sole medical therapy was used in only 16.1% of STEMI
patients. Overall, PCI was performed in 517 (42.2%) of 1224
patients, and 152 (12.4%) of 1223 patients had coronary artery
bypass surgery (CABG). Patients who had CABG were signifi-
cantly older than those who had PCI (62.5  9.4 vs 59.6  11.0,
p ¼ 0.003). Though males were more likely to have CAG than
females (81.1% vs 74.7%; p ¼ 0.01), there was statistically no
significant gender difference in the rate of interventions: PCI
(male 36.5%; female 30.5%, p ¼ 0.06) and CABG (male 12.9%;
female 10.0%, p ¼ 0.17). Arrhythmias (3.7%), resuscitated car-
diac arrest (1.8%) and intracardiac thrombus (1.5%) were the
leading complications (Table 4).
There were 37 (2.5%) deaths at 1 year of follow up Mortality
rates at 7 days, 30 days, 6 months and 1 year were 0.4%, 0.7%,
2.0% and 2.5%, respectively. Mortality was fairly evenly spread
during the first and second halves of the 1 year following ACS
in the STEMI compared to NSTEMI/UA group (41.7% vs 58.3%)
while deaths occurred predominantly during the second half
of the year in the NSTEMI/UA patients (80% vs 20%). Mortality
increased though at statistically insignificant levels with
increasing age group: [11/662 (1.7%), 13/459 (2.8%) and 13/346
(3.8%); p ¼ 0.10] in patients aged 60 years, 61e70 years and
>70 years, respectively. Mortality increased at statistically
significant level across increasing gradient of risk39%
29%
31%
1%
Single
Double
Tripple
Normal
Fig. 3 e Grouping of coronary vessel lesion.
Table 3 e Treatment and intervention.
Drug treatment Total no of
patients
Patients
treated n
(%)
Acetyl salicylic acid (Aspirin) 1468 1441 (98.2)
Clopidogrel 1468 1396 (95.1)
Lipid lowering drugs 1453 1383 (95.2)
ACEI or ARB 1245 630 (50.6)
Beta blocker (BB) 1245 1035 (83.1)
ACEI or ARB or BB 1245 1199 (96.3)
Calcium channel blocker
(CCB)
1245 148 (11.9)
Anticoagulant use 1468 624 (42.5)
LMWH 1468 459 (31.3)
Unfractionated heparin 1468 165 (11.2)
Thrombolysis 498 101 (20.3)
PCI 1223 515 (42.1)
CABG 1223 152 (12.4)
ACEI: Angiotensin converting enzyme inhibitor. ARB: Angiotensin
receptor blocker. BB: Beta blocker. CABG: Coronary artery bypass
graft. CCB: Calcium channel blocker. LMWH: Lowmolecular weight
heparin. PCI: Percutaneous coronary intervention.
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(1.8%) and high risk 19/174 (10.9%); p < 0.0001]. At 1 year of
follow up 59/1463 (4.0%), 26/1468 (1.8%), 16/1468 (1.1%), and
5/1171 (0.4%) patients had reinfarction, resuscitated cardiac
arrest and major bleeding, respectively. Composite major
adverse cardiac event (deaths, myocardial infarction, stroke,
cardiac arrest and bleeding) at 1 year was 9.7%.
The deceased and survivors at 1 year are compared in
Table 5. Compared to the survivors the deceased were older
(66.8 10.7 vs 62.0 11.2 years; p¼ 0.01) and had higher serum
creatinine level (1.9  1.7 vs 1.1  1.6 mg/dl, p < 0.01) and
higher frequency of hospital admissions (2.7 2.0 vs 1.2 0.5).
The deceased also had higher proportion of patients with
troponin positive I status (96.0 vs 65.7%, p < 0.0001), TIMI Risk
Factors 3 (36.1 vs 20.8%, p ¼ 0.02), and high risk class (60.6 vs
14.4%), severe LV dysfunction (18.9 vs 6.6%, p ¼ 0.003), CABG
(25.0 vs 2.1%) and3 CAD risk factors (64.7 vs 39.7%, p¼ 0.003).
The mean duration of first hospital admission was 5.5  7.2
days (median 4 days). It did not differ among the deceased and
survivors. Frequency of hospitalization ranged from 1 to 13
and was higher among NSTEMI/UA than STEMI patients
(1.3  0.7 vs 1.2  0.5, p < 0.0001) and higher among theTable 4 e Complications.
Complications No (%)
Arrhythmia 42/1130 (3.7)
Resuscitated cardiac arrest 26/1468 (1.8)
Intracardiac thrombus 18/1182 (1.5)
Stroke 16/1468 (1.1)
Ventricular aneurysm 14/1468 (1.0)
Cardiogenic shock 13/1468 (0.9)
Chordae rupture 6/1468 (0.5)
Major bleeding 5/1171 (0.4)
Ventricular septal rupture 2/1468 (0.1)
Free wall rupture 1/1140 (0.01)deceased compared to survivors at 1 year (2.6 2.0 vs 1.2 0.5,
p < 0.0001).
On univariate analysis factors associated with mortality
(Table 6) included concomitant severe left ventricular systolic
and diastolic dysfunction (OR ¼ 20.0, 95% CI ¼ 6.63e69.4);
troponin I positive status (OR ¼ 12.56, 95% CI ¼ 1.78e25.23);
high risk class (OR ¼ 11.96, 95% CI ¼ 5.31e27.34); severe left
ventricular dysfunction (OR ¼ 3.0, 95% CI ¼ 1.28e8.15); CAD
risk factors 3 (OR ¼ 2.79, 95% CI ¼ 1.31e6.03); CABG
(OR ¼ 2.41, 95% CI ¼ 1.28e5.5); TIMI risk factors 3 (OR ¼ 2.19,
95% CI ¼ 1.0e4.73). Multiple logistic regression analysis
involving age, gender, risk class, CAD and TIMI risk factors 3
each showed that only positive troponin status independently
predicted mortality (p ¼ 0.002).
During the study period (2008e2009), there were trends
(Fig. 4) towards increasing annual rates of admission for ACS,
coronary angiography, PCI, and use of ACEI inhibitors/ARB
and beta blockers. Mortality and CABG rates fell over the same
period (Fig. 4).4. Discussion
This study provides information on descriptive epidemiology,
practice patterns and outcomes of patients with ACS in a
specialized cardiac centre in India. We observed similar de-
mographic and CAD risk profiles to the previous reports from
Indian and some other developing nations.5,6,9e11 However,
our patients were relatively older and had higher prevalence
of diabetes, dyslipidaemia and prior myocardial infarction
(MI). The proportion of patients over 70 years of age in the
current report, for example, almost doubles that in the
CREATE Registry in India.6 Our patients were nonetheless
younger than the Caucasian ACS population.12 Although the
relatively higher age of the current study population may be
incidental, it could be a reflection of an epidemiological evo-
lution in the demography of Indian CAD patients. This trend
has been described in the Caucasians. The average age of ACS
patients, for example, increased over a 17-year period from
58.4 to 63.4 years in Montreal Heart Institute.13 As in previous
reports,6,9,10 women were older and had higher rates of hy-
pertension and diabetes mellitus, and lower rate of cigarette
smoking than men.
The proportion of patients with STEMI in the current study
is lower than the values previously reported in India6,9 but
about 35% was observed in the Europeans.12 Recent data from
other developing nations10,11 similarly showed STEMI rates
lower than reported in the CREATE study. As acknowledged in
the CREATE report,6 a sizable proportion of patients had no
cardiac enzyme test and this might have influenced patients’
categorization. Compared to NSTEMI/UA, our STEMI patients,
like in previous reports from India and other developing
nations,6,7,9e11 were younger and more likely to be males.
Key pharmacotherapy, particularly, antiplatelet treatment
that included clopidogrel was used at a rate quite higher than
many previous reports from India and comparable to the
developed nations. About half of the referred patients had
dual antiplatelet therapy prior to referral. This suggests an
increasing awareness of current evidence-based guidelines in
the management of ACS among Indian general physicians.
Table 5 e Univariate comparison of deceased and survivors of ACS at 1-year post event.
Parameter Deceased Survivors Total p-value
No (%) 37 (2.5) 1431 (97.5) 1468 (100)
Age (years) 66.8  10.7 62.0  11.2 62.2  11.2 0.01
Age >70 years 13 (35.1) 333 (23.4) 805 (54.8) 0.09
Male n (%) 30 (81.1) 1074 (75.1) 1104 (75.1) 0.40
STEMI 12 (32.4) 486 (34.0) 498 (33.9) 0.85
NSTEMI/UA 25 (67.6) 945 (66.0) 970 (66.1) 0.85
Troponin I þve (%) 24/25 (96.0) 258/393 (65.7) 282/418 (67.5) 0.002
Previous MI (%) 15/36 (41.7) 406/1265 (32.1) 421/1301 (32.4) 0.23
CABG n (%) 9/36 (25.0) 143/1179 (12.2) 152/1215 (12.5) 0.02
Serum Cr (mg/dl) 1.9  1.7 1.1  1.6 1.2  4.0 0.01
Severe LVSD n (%) 7/37 (18.9) 85/1286 (6.6) 92/1323 (7.0) 0.003
Both LVSD & LVDD n (%) 25/29 (86.2) 246/1045 (23.5) 271/1070 (25.3) <0.0001
Risk factor 3 (%) 22/34 (64.7) 558/1407 (39.7) 580/1441 (40.2) <0.003
Frq hospitalized 2.7  2.0 1.2  0.5 1.2  0.6 <0.0001
TIMI RF 3 (%) 12/33 (36.4) 288/1105 (20.8) 300/1138 (26.4) <0.02
High risk 20/33 (60.6) 174/1379 (14.4) 194/1412 (13.7) <0.0001
CABG: Coronary artery bypass graft. Frq: Frequency. LVSD: Left ventricular systolic dysfunction. LVDD: Left ventricular diastolic dysfunction.
TIMI RF: Thrombolysis in myocardial infarction risk factors.
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of BB was very high, and almost all patients received either BB
or ACEI/ARB or both. The rate of reperfusion therapy was
higher in the current than previous reports from India.6,9 In
the STEMI group, for example, almost 75% of patients had
either primary PCI or thrombolysis, and only 16.1% had sole
medical therapy. The remaining STEMI patients had surgical
reperfusion. Though second generation fibrinolytic therapy
including tenecteplase and reteplase has been shown to
improve outcomes in STEMI patients, streptokinase remains
the predominantly used thrombolytic agent in India probably
because of financial constraint.
Coronary angiography rate was higher than previously
reported in India6,9 and comparable with the findings in the
developed nations.12 The PCI rate was also higher than pre-
viously reported in India. Patients’ choice of treatment strat-
egy, disease severity, financial difficulties and old age might
have influenced PCI rate in the current report. Patients who
had PCI were, for example, significantly younger than those
who had only medical treatment. Though coronary angiog-
raphy rate was higher in males than females, there were no
gender differences in the rates of PCI and CABG. This is similarTable 6 e Factors associated with mortality.
Factors Odd ratio 95% CI p-value
Both LVSD & LVDD 20.0 6.63e69.40 <0.0001
Troponin þve status 12.56 1.78e25.13 0.002
High risk class 10.65 4.95e23.13 0.001
Severe LVSD 3.0 1.28e8.15 0.03
Risk factor 3 2.79 1.31e6.03 0.003
CABG 2.41 1.28e5.50 0.02
Diabetes 2.24 1.0e5.15 0.03
TIMI RF 3 2.19 1.0e4.73 0.02
CABG: Coronary artery bypass graft. Frq: Frequency. LVSD: Left
ventricular systolic dysfunction. LVDD: Left ventricular diastolic
dysfunction. TIMI RF: Thrombolysis in myocardial infarction risk
factors.to some previous reports14 but contrasts other reports that
suggested women with ACS are less aggressively managed.15
The 1-year mortality rate observed in the current report is
lower than the values in most multicentre Registries.6,10e12 It
is however comparable to the findings in some single centre-
based studies.13,16 The influence of hospital setting on the
outcomes of ACS has been suggested. In the AMIS Registry,17
hospital categorized as grade A which is characterized by
24 h coronary care unit, cardiac catheterization and cardiac
surgery services had lowermortality than category B hospitals
where these services were not obtainable or obtainable to the
same extent (2.8 vs 4.0%). Similarly, annual mortality rate was
reported to have dropped over the years to as low as 1.5% inFig. 4 e Trends in interventions and mortality. ACEI:
Angiotensin converting enzyme inhibitor. ARB:
Angiotensin receptor blocker. BB: Beta blocker. CAG:
Coronary angiogram; CABG: Coronary arteries bypass
graft. PCI: Percutaneous coronary intervention.
i n d i a n h e a r t j o u r n a l 6 6 ( 2 0 1 4 ) 1 5 6e1 6 3162Montreal Heart Institute, a specialized cardiac centre.13 This
was attributed to maximal utilization of available resources
and best practices including adherence to evidenced based
guidelines with proven benefits. These observations might
have partly informed the emerging advocates of designated
specialized cardiac centres for the care of ACS patients.
Though it has been consistently believed that Indians with
ACS have higher mortality than the whites,2,6 a recent meta-
analysis of 4 recently published studies showed that the
prognosis of manifestation of CAD in South Asian people is
not worse than Whites, and the increased coronary mortality
rates in the former are due to the higher incidence of fatal and
non-fatal CAD.18 Another recent comparison of a South Asian
STEMI populationwith the Europeans showed that though the
Asian STEMI patients were younger and more likely to be
diabetic, the survival at discharge was similar compared to
Europeans.19 It is nonetheless probable that the low mortality
rate in the current report may be because our study popula-
tion belonged predominantly to low/intermediate risk group
with generally low rates of severe complications. Mortality
rate was, for example, high in the high-risk group.
The clinical determinants of mortality in the current report
are largely similar to the findings in previous studies.11,19e22
Only cardiac troponin I passed as an independent predictor
of mortality. The prognostic role of this cardiac biomarker has
been previously documented.21 We observed higher serum
creatinine among the deceased compared to the survivors.
This is similar to the findings in the GRACE study where
creatinine clearance was an important predictor of mortal-
ity.22 In the current report, gender did not influence 1-year
mortality. This is similar to some of the previous reports23 but
at variance with some others.24 It was recently observed that
mortality rates are higher among young womenwith ACS, but
this difference tends to disappear with aging, and long term
prognosis is similar or even better among older women.25 The
prevalence of metabolic syndromewas not investigated in the
current report. We however observed clustering of cardio-
vascular risk factors in about 40% of our patients. This is
similar to the reported 45% prevalence rate of metabolic
syndrome in ACS patients,26 and like metabolic syndrome,
clustering of CAD risk factors adversely affected the outcome
of ACS in the current report.
During the3 years studyperiodweobserveda trend towards
increasing rates of admission for ACS, interventions and use of
key pharmacotherapy, and a fall inmortality. Aminimal fall in
surgical revascularization was also demonstrated. Some of
these observations are similar to the findings inMontreal Heart
Institute though the rate of surgical revascularization was sta-
ble during the period of study in this institute.13 Our findings
need tobe confirmed in a studyover a longerperiod as 3 years is
insufficient to determine temporal changes. They nonetheless
probably indicate that the CAD epidemic is still on-going in
India, and that there is increased awareness of the disease
among the populace and improved compliance with evidence-
based treatment guidelines among the physicians.
This study is not without limitations. Out-of-hospital
events were not captured. However, the lost to follow up
rate was low (3.7%) making its effect on overall outcome being
probably minimal. As expected in all retrospective studies,
there was missing data. Being a single center and hospital-based experience, our results cannot be generalized. It how-
ever illustrates the potential favorable outcome of ACS in a
tertiary cardiac care setting.
In conclusion, our data demonstrated ACS patient popula-
tion that is relatively older than previously described in India.
Evidence-based pharmacotherapy and interventions aswell as
outcomes were favorably comparable to the data from devel-
oped nations. Trends towards increasing admission rate for
ACS, utilization of therapeutic advances and fall in mortality
were observed.Conflicts of interest
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